Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab.

摘要

Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu disease, is an arteriovenous malformation of various organs and systems due to fibrovas-cular dysplasia. This results in recurrent and sometimes severe bleeding, of which epistaxis is the most common. Hepatic arteriovenous malformations may cause arteriovenous shunting within the liver, ischemic hepatobiliary damage, and high-output cardiac failure .